Therapeutic methods in Age-Related Macular Degeneration: Recent advances and future perspectives
DOI:
https://doi.org/10.33448/rsd-v14i6.49025Keywords:
anti-VEGF, Emerging therapies, Macular degeneration, Eye health.Abstract
This study aims to conduct an integrative literature review, mapping established and emerging therapeutic approaches for age-related macular degeneration (AMD), with a special focus on clinical effectiveness, cost-effectiveness, and feasibility of implementation in public health systems. This research investigated available and emerging therapies for AMD, emphasizing clinical efficacy, treatment durability, and incorporation into public policy. The analysis highlighted traditional antiangiogenic agents such as ranibizumab and aflibercept, while discussing their limitations regarding cost and access. Emerging agents like faricimab and OPT-302 were identified as promising due to longer intervals between applications. In addition, innovative therapies such as cell and gene therapy showed potential to modify the course of the disease, especially in advanced cases. The study reinforces the importance of considering equity in access to treatments and the need for evidence-based public health policies. The abstract concludes by emphasizing the relevance of further studies to strengthen the clinical effectiveness, cost-effectiveness, and real-world applicability of the most modern therapeutic approaches.
Downloads
References
Agostini, H., Abreu, F., Baumal, C. R., Chang, D. S., Csaky, K. G., Demetriades, A. M., et al. (2024). Faricimab for neovascular age-related macular degeneration and diabetic macular edema: From preclinical studies to phase 3 outcomes. Graefe’s Archive for Clinical and Experimental Ophthalmology, 262, 3437–3451. https://doi.org/10.1007/s00417-024-06531-9
Anima. (2014). Manual revisão bibliográfica sistemática integrativa: a pesquisa baseada em evidências. Grupo Anima. https://biblioteca.cofen.gov.br/wp-content/uploads/2019/06/manual_revisao_bibliografica-sistematica-integrativa.pdf
Barros, C. G., Moraes, H. V., & Silva, M. L. (2018). Perfil epidemiológico das aplicações intravítreas no SUS. Revista Brasileira de Oftalmologia, 77(3), 200–207. https://doi.org/10.5935/0034-7280.20180028
Brasil. (2021). Degeneração Macular Relacionada à Idade: principais causas de cegueira em idosos. Brasília: Ministério da Saúde.
CONITEC. (2021). Relatório de Recomendação: aflibercepte para DMRI. Comissão Nacional de Incorporação de Tecnologias no SUS. Brasília: Ministério da Saúde.
Crossetti, M. G. M. (2012). Revisión integradora de la investigación en enfermería: el rigor científico que se le exige. Revista Gaúcha de Enfermagem, 33(2), 8–9.
Ferris, F. L., Wilkinson, C. P., Bird, A., Claxton, Z., Bailey, I. L., et al. (2013). Clinical classification of age-related macular degeneration. Ophthalmology, 120(4), 844–851.
Fleck, B. W., Kasper, L. A., & Bailey, J. C., et al. (2014). Genetic predispositions in age-related macular degeneration. Ophthalmic Genetics, 35(4), 183–189.
Girgis, C. M., Phan, K., & McLure, T. M. (2023). Treatment of dry age-related macular degeneration: A review. Clinical and Experimental Ophthalmology, 51(8), 835–852. https://doi.org/10.1111/ceo.14294
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J. F., Kaiser, P. K., Nguyen, Q. D., et al. (2012). Intravitreal aflibercept for neovascular age-related macular degeneration: 2-year results of the VIEW 1 and VIEW 2 studies. Ophthalmology, 119(12), 2537–2548.
Jackson, T. L., Nguyen, Q. D., Kaiser, P. K., Brown, D. M., Holz, F. G., Heier, J. S., et al. (2023). A randomized controlled trial of OPT-302 combined with ranibizumab for neovascular age-related macular degeneration. Ophthalmology Science, 130(6), 588–597. https://doi.org/10.1016/j.ophtha.2023.02.001
Jonas, J. B., Cheung, C. M. G., & Panda-Jonas, S. (2017). Updates in the epidemiology and risk factors of age-related macular degeneration. Progress in Retinal and Eye Research, 58, 89–114.
Koizumi, H., Iida, T., & Fung, A. E. (2024). Comparative efficacy and safety of faricimab and aflibercept: A systematic review. Retina, 262, 2439–2448. https://doi.org/10.1007/s00417-024-06377-1
Lasalvia, P., Rodríguez, Ó., & Ceballos, M. (2023). Análisis de minimización de costos de brolucizumab para la DMAEh en Colombia. Revista de la Sociedad Colombiana de Oftalmología, 56(1), 6–15. https://doi.org/10.24875/RSCO.22000019
Liegl, R., Sennlaub, F., & Hager, A. (2023). Targeting key angiogenic pathways with bispecific antibody faricimab: A new therapeutic option for retinal diseases. Progress in Retinal and Eye Research, 96, 101013. https://doi.org/10.15252/emmm.201505889
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., ... & Tremblay, J. P. (2021). Current clinical applications of in vivo gene therapy with AAVs. Molecular Therapy, 29(2), 464–488. https://doi.org/10.1016/j.ymthe.2020.12.007
Mettu, P. S., Wielgus, A. R., & Bhutto, I. A. (2020). Neovascular macular degeneration: A review of etiology, risk factors, and recent advances. Vision Research, 188, 10–20. https://doi.org/10.3390/ijms22031170
Ministerio de Salud y Protección Social. (2021). Dictamen preliminar de evaluación de tecnología: aflibercepte para DMRI. Bogotá: Minsalud.
Muradas, D. B., Urbano, J. V. F., Oliveira, P. S., & Silva, S. A. R. (2020). Degeneração macular relacionada à idade: o potencial terapêutico das células-tronco. Revista Médica de Minas Gerais, 30(Sup.2). https://doi.org/10.5935/2238-3182.v30supl.2.02
Nguyen, Q. D., Brown, D. M., Jaffe, G. J., Ying, G. S., & Rosenfeld, P. J. (2023). Long-term outcomes of anti-VEGF therapy in AMD: The SEVEN-UP study. Ophthalmology Retina. https://doi.org/10.1186/s12886-023-02843-2
Nichani, P. A. H., Popovic, M. M., Mihalache, A., Pathak, A., Muni, R. H., Wong, D. T. W., & Kertes, P. J. (2024). Efficacy and safety of intravitreal faricimab in neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion: A meta-analysis. Ophthalmologica, 247(5–6), 355–372. https://doi.org/10.1159/000541662
Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologia da pesquisa científica [E-book]. Ed. UAB/NTE/UFSM. https://repositorio.ufsm.br/bitstream/handle/1/15824/Lic_Computacao_Metodologia-Pesquisa-Cientifica.pdf
Rodríguez, F. J., Lasalvia, P., & Vaca, C. (2015). Análisis de costo-efectividad de tratamientos anti-VEGF en la DMRI. Instituto de Evaluación Tecnológica en Salud (IETS), Bogotá.
Rohrbacher, F., & Vieira de Souza, C. (2018). Análise da variação da pressão intraocular após injeções de ranibizumabe. Revista Brasileira de Oftalmologia, 77(1), 34–37. https://doi.org/10.5935/0034-7280.20180007
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006). Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine, 355, 1419–1431.
Sahni, J., Dugel, P. U., Patel, S. S., Khanani, A. M., Wykoff, C. C., Hariprasad, S. M., & Nguyen, Q. D. (2023). Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: A systematic review and meta-analysis. Clinical Ophthalmology, 17, 389–405. https://doi.org/10.1001/jamaophthalmol.2020.2685
Samacá-Samacá, D., Hernández-Castillo, C., Prieto-Pinto, L., Rodríguez, F., Sardi, C., Ocampo, H., Kock, J., & Hernández, F. (2024). Efficacy and safety of faricimab for neovascular age-related macular degeneration: A systematic review and network meta-analysis. BMJ Open Ophthalmology, 9, e001702. https://doi.org/10.1136/bmjophth-2024-001702
Schmidt-Erfurth, U., Brown, D. M., Chang, W. Q., et al. (2014). The potential of gene therapy and photodynamic therapy in the treatment of age-related macular degeneration. Journal of Ophthalmic Research, 39(4), 223–240.
Snyder, H. (2019). Literature review as a research methodology: An overview and guidelines. Journal of Business Research, 104, 333–339.
Sobczak, K., Kowalski, B., & Kwiatkowski, J. (2019). Genetic polymorphisms in the CFH and ARMS2 genes and their association with AMD. Investigative Ophthalmology & Visual Science, 60, 721–729.
Souza, P. D. Q., Melo, R. A., & Batista, M. G. (2021). Acessibilidade e custos dos tratamentos anti-VEGF no Brasil. Revista Brasileira de Oftalmologia, 80(3), 212–218.
Tan, S. Z., Hewitt, A. W., & Cheng, C. Y. (2023). Neovascular age-related macular degeneration: Current treatment and emerging therapies. International Journal of Molecular Sciences, 24(9), 7966. https://doi.org/10.3390/ijms24097966
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C. Y., & Wong, T. Y. (2014). Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. The Lancet Global Health, 2(2), e106–e116.
Zonta, M. A., Rodrigues, P. A., & Silva, F. G. (2018). Distorção visual e perda de acuidade em pacientes com DMRI. Arquivos Brasileiros de Oftalmologia, 81(5), 362–368.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Eduardo Guimarães de Paula; Heloisa Miura; Mauro da Silva Mello Dockhorn
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
